- Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
-
Shin JY, Park HM, Lee MY, Jeon JY, Yoo HJ, Ye BD
- KMID: 2522348
- Gut Liver.
- 2021 Nov;15(6):867-877.
- doi: 10.5009/gnl20353
Background/Aims: Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated,... -
- CITED
-
- Close
- SHARE
-
- Close
- Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
-
Jang BK
- KMID: 2504505
- Clin Mol Hepatol.
- 2020 Jul;26(3):312-314.
- doi: 10.3350/cmh.2020.0099
-
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
-
Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH
- KMID: 2373148
- Clin Mol Hepatol.
- 2016 Dec;22(4):443-449.
- doi: 10.3350/cmh.2016.0037
BACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
-
Song BC
- KMID: 2373147
- Clin Mol Hepatol.
- 2016 Dec;22(4):439-442.
- doi: 10.3350/cmh.2016.0108
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Reduction of Disease Activity in Patient with Relapsing-Remitting Multiple Sclerosis after Switching to Teriflunomide from Interferon Beta
-
Shin KS, Park JG, Park MS
- KMID: 2153170
- J Korean Neurol Assoc.
- 2016 Feb;34(1):77-79.
- doi: 10.17340/jkna.2016.1.17
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
